RecruitingNCT03280394

Liquid Biopsy in Mature B-cell Tumors

Prospective, Observational, Multi-centred, Non-interventional Research Project on Plasma Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Tumor Management


Sponsor

Oncology Institute of Southern Switzerland

Enrollment

444 participants

Start Date

Sep 1, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Male or female adults 18 years or older
  • Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria
  • Willing and able to comply with scheduled study procedures
  • Evidence of a signed informed consent

Interventions

DIAGNOSTIC_TESTLiquid Biopsy

Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.


Locations(1)

Institute of Oncology Research

Bellinzona, Canton Ticino, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03280394


Related Trials